Virginia Pharmacy Intern Registration Exam Prep Document
| 2026/2027 Edition | 200 Verified Questions - 170 Questions
with Answers
Virginia Pharmacy Intern Registration Exam 2026-170 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for pharmacy interns
seeking registration in the Commonwealth of Virginia. It contains 200 verified practice questions that
mirror the format and content of the actual Virginia Pharmacy Intern Registration Exam. Each question
is accompanied by a correct answer and a detailed rationale to reinforce understanding of key
pharmacological and legal principles. Updated for the 2026/2027 academic year, this resource is an
essential tool for achieving a passing score and ensuring compliance with state regulations.
Key Features:
Pharmacy Law and Ethics (Virginia and Federal)
Drug Classification and Scheduling (Controlled Substances)
Pharmacology and Therapeutics (Major Drug Classes)
Pharmaceutical Calculations and Compounding
Dispensing Processes and Prescription Processing
Drug Interactions and Adverse Effects
Patient Safety and Medication Errors
Over-the-Counter (OTC) Products and Self-Care
Biologics, Biosimilars, and Immunizations
Pharmacy Operations and Inventory Management
Professional Communication and Patient Counseling
Regulatory Compliance and Documentation
Infection Control and Sterile Compounding
Special Populations (Pediatric, Geriatric, Pregnancy)
Pharmacogenomics and Personalized Medicine
Emerging Therapies and Drug Updates
Public Health Initiatives and Substance Abuse Prevention
Quality Assurance and Continuous Improvement
Updates for 2026:
- Incorporates 2026 Virginia Board of Pharmacy regulation changes
- Includes new questions on recent drug approvals and recalls
- Updated to reflect current USP <797> and <800> standards
- Revised rationales to align with latest clinical guidelines
- Enhanced coverage of telepharmacy and digital health trends
Abstract:
This exam preparation document serves as an authoritative study guide for the Virginia Pharmacy Intern
Registration Exam, a licensure requirement for pharmacy interns in the state. The content is systematically
organized to cover all domains tested, including federal and state pharmacy law, pharmacology, therapeutics, and
professional practice standards. Each of the 200 practice questions is designed to assess critical thinking and
application of knowledge in real-world scenarios. Detailed rationales accompany every answer, explaining not
Page 1
,only the correct choice but also why the distractors are incorrect, thereby facilitating deeper learning. The
material is current with 2026/2027 regulations and includes updates on drug safety alerts, compounding
standards, and emerging therapeutic areas. This document is an invaluable resource for interns aiming to
demonstrate competency and uphold the highest standards of patient care.
Keywords:
Virginia pharmacy intern exam, Pharmacy law, Pharmacology, Therapeutics, Drug calculations, Patient safety,
Compounding, Exam prep 2026
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale that explains the underlying concept and clinical reasoning. Additionally,
each rationale includes an explanation of why the incorrect options are not the best choices, enhancing the
educational value.
Compliance Checklist:
Aligned with Virginia Board of Pharmacy regulations
Updated to reflect 2026/2027 exam blueprint
Includes rationales for all answers
Covers all major content areas
Suitable for self-assessment and review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacy Law and Ethics 1-30 Federal laws, Virginia regulations, HIPAA, 15%
ethical principles
Pharmacology and Therapeutics 31-70 Cardiovascular, CNS, endocrine, 20%
antimicrobials, oncology
Pharmaceutical Calculations and 71-90 Dosage calculations, IV flow rates, 10%
Compounding compounding techniques
Dispensing and Prescription 91-110 Prescription interpretation, drug utilization 10%
Processing review, labeling
Drug Interactions and Adverse 111-130 Drug-drug interactions, adverse drug 10%
Effects reactions, contraindications
Patient Safety and Medication 131-150 Error prevention, high-alert medications, 10%
Errors root cause analysis
OTC Products and Self-Care 151-165 Common OTC medications, self-care 7.5%
recommendations, red flags
Biologics, Biosimilars, and 166-175 Vaccines, monoclonal antibodies, biosimilar 5%
Immunizations interchangeability
Pharmacy Operations and 176-185 Inventory management, third-party billing, 5%
Management workflow efficiency
Professional Communication and 186-195 Counseling techniques, health literacy, 5%
Patient Counseling cultural competence
Special Populations and 196-200 Pediatrics, geriatrics, pregnancy, 2.5%
Emerging Topics pharmacogenomics, new drugs
Page 2
,Q1. A pharmacist receives a prescription for a controlled substance bearing a
prescriber's DEA number that fails the checksum validation. Which action is legally
required in Virginia?
A. Dispense the prescription and notify the prescriber later
B. Contact the prescriber to verify the DEA number and correct it before dispensing
C. Refuse to fill and report to the DEA
D. Use the NPI number instead to validate the prescription
Correct Answer: B. Contact the prescriber to verify the DEA number and correct it
before dispensing
Rationale: Virginia regulations require the pharmacist to verify the DEA number and
ensure it is valid. If it fails validation, the pharmacist must not dispense until the
prescriber confirms and corrects the number. Reporting to the DEA is only for suspected
diversion or forgery, not for an administrative error.
Why Wrong:
A - Dispensing without correcting an invalid DEA number violates federal and state
law and could result in penalties.
C - Reporting to the DEA is excessive unless there is evidence of fraud or diversion,
not a simple typographical error.
D - The NPI is not a substitute for a DEA number on controlled substance
prescriptions.
Reference: Virginia Board of Pharmacy Regulations, 18 VAC 110-20-50; DEA
Practitioner's Manual
Q2. A patient on chronic warfarin therapy is prescribed metronidazole for a dental
infection. The pharmacist notes the interaction. What is the most appropriate action
regarding warfarin management?
A. Discontinue warfarin for the duration of metronidazole therapy
B. Reduce the warfarin dose by 50% and monitor INR closely
C. Continue warfarin unchanged and recheck INR in 1 week
D. Hold warfarin and start bridging with enoxaparin
Correct Answer: B. Reduce the warfarin dose by 50% and monitor INR closely
Rationale: Metronidazole inhibits CYP2C9, decreasing warfarin metabolism and
increasing INR. Proactive dose reduction (often 50%) with close INR monitoring is
recommended to prevent bleeding. Discontinuation or bridging is not standard for a short
course.
Why Wrong:
A - Discontinuing warfarin increases thromboembolic risk without a clear indication
for bridging.
C - Continuing unchanged risks supratherapeutic INR and bleeding.
Page 3
, D - Bridging is only for perioperative or high-thrombotic-risk situations, not for
antibiotic interaction.
Reference: Hansten & Horn, Drug Interactions Analysis and Management; Ansell et al.,
CHEST Guidelines
Q3. According to Virginia law, which of the following must be included on the label of
a dispensed prescription medication?
A. The drug's brand name and manufacturer
B. The prescriber's DEA number
C. The date of dispensing and the pharmacy's telephone number
D. The patient's diagnosis and the drug's expiration date
Correct Answer: C. The date of dispensing and the pharmacy's telephone number
Rationale: Virginia law requires the date of dispensing and the pharmacy's name, address,
and telephone number on the label. Brand name, DEA number, diagnosis, and expiration
date are not required on patient labels.
Why Wrong:
A - Brand name and manufacturer are not required by state law; generic name is
sufficient.
B - DEA number is for the prescription record, not the patient label.
D - Diagnosis is never required on a label; expiration date may be on the container but
not mandated on the label.
Reference: 18 VAC 110-20-160; Virginia Drug Control Act
Q4. A patient has a serum creatinine of 1.4 mg/dL, weighs 72 kg, and is 65 years old.
Calculate the estimated creatinine clearance using the Cockcroft-Gault equation.
Which value is closest?
A. 48 mL/min
B. 60 mL/min
C. 72 mL/min
D. 84 mL/min
Correct Answer: A. 48 mL/min
Rationale: Using Cockcroft-Gault: CrCl = [(140 - age) × weight] / (72 × SCr). For male:
(140-65=75) × 72 = 5400; 72 × 1.4 = 100.8; 5400/100.8 53.6 mL/min. For female,
multiply by 0.85. The closest option is 48 mL/min (likely assuming female).
Why Wrong:
B - 60 mL/min is too high and likely reflects an error in arithmetic or not adjusting for
age.
C - 72 mL/min would be if the serum creatinine were 1.0 mg/dL, not 1.4.
D - 84 mL/min is too high and suggests a miscalculation of the denominator.
Page 4
| 2026/2027 Edition | 200 Verified Questions - 170 Questions
with Answers
Virginia Pharmacy Intern Registration Exam 2026-170 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for pharmacy interns
seeking registration in the Commonwealth of Virginia. It contains 200 verified practice questions that
mirror the format and content of the actual Virginia Pharmacy Intern Registration Exam. Each question
is accompanied by a correct answer and a detailed rationale to reinforce understanding of key
pharmacological and legal principles. Updated for the 2026/2027 academic year, this resource is an
essential tool for achieving a passing score and ensuring compliance with state regulations.
Key Features:
Pharmacy Law and Ethics (Virginia and Federal)
Drug Classification and Scheduling (Controlled Substances)
Pharmacology and Therapeutics (Major Drug Classes)
Pharmaceutical Calculations and Compounding
Dispensing Processes and Prescription Processing
Drug Interactions and Adverse Effects
Patient Safety and Medication Errors
Over-the-Counter (OTC) Products and Self-Care
Biologics, Biosimilars, and Immunizations
Pharmacy Operations and Inventory Management
Professional Communication and Patient Counseling
Regulatory Compliance and Documentation
Infection Control and Sterile Compounding
Special Populations (Pediatric, Geriatric, Pregnancy)
Pharmacogenomics and Personalized Medicine
Emerging Therapies and Drug Updates
Public Health Initiatives and Substance Abuse Prevention
Quality Assurance and Continuous Improvement
Updates for 2026:
- Incorporates 2026 Virginia Board of Pharmacy regulation changes
- Includes new questions on recent drug approvals and recalls
- Updated to reflect current USP <797> and <800> standards
- Revised rationales to align with latest clinical guidelines
- Enhanced coverage of telepharmacy and digital health trends
Abstract:
This exam preparation document serves as an authoritative study guide for the Virginia Pharmacy Intern
Registration Exam, a licensure requirement for pharmacy interns in the state. The content is systematically
organized to cover all domains tested, including federal and state pharmacy law, pharmacology, therapeutics, and
professional practice standards. Each of the 200 practice questions is designed to assess critical thinking and
application of knowledge in real-world scenarios. Detailed rationales accompany every answer, explaining not
Page 1
,only the correct choice but also why the distractors are incorrect, thereby facilitating deeper learning. The
material is current with 2026/2027 regulations and includes updates on drug safety alerts, compounding
standards, and emerging therapeutic areas. This document is an invaluable resource for interns aiming to
demonstrate competency and uphold the highest standards of patient care.
Keywords:
Virginia pharmacy intern exam, Pharmacy law, Pharmacology, Therapeutics, Drug calculations, Patient safety,
Compounding, Exam prep 2026
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale that explains the underlying concept and clinical reasoning. Additionally,
each rationale includes an explanation of why the incorrect options are not the best choices, enhancing the
educational value.
Compliance Checklist:
Aligned with Virginia Board of Pharmacy regulations
Updated to reflect 2026/2027 exam blueprint
Includes rationales for all answers
Covers all major content areas
Suitable for self-assessment and review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacy Law and Ethics 1-30 Federal laws, Virginia regulations, HIPAA, 15%
ethical principles
Pharmacology and Therapeutics 31-70 Cardiovascular, CNS, endocrine, 20%
antimicrobials, oncology
Pharmaceutical Calculations and 71-90 Dosage calculations, IV flow rates, 10%
Compounding compounding techniques
Dispensing and Prescription 91-110 Prescription interpretation, drug utilization 10%
Processing review, labeling
Drug Interactions and Adverse 111-130 Drug-drug interactions, adverse drug 10%
Effects reactions, contraindications
Patient Safety and Medication 131-150 Error prevention, high-alert medications, 10%
Errors root cause analysis
OTC Products and Self-Care 151-165 Common OTC medications, self-care 7.5%
recommendations, red flags
Biologics, Biosimilars, and 166-175 Vaccines, monoclonal antibodies, biosimilar 5%
Immunizations interchangeability
Pharmacy Operations and 176-185 Inventory management, third-party billing, 5%
Management workflow efficiency
Professional Communication and 186-195 Counseling techniques, health literacy, 5%
Patient Counseling cultural competence
Special Populations and 196-200 Pediatrics, geriatrics, pregnancy, 2.5%
Emerging Topics pharmacogenomics, new drugs
Page 2
,Q1. A pharmacist receives a prescription for a controlled substance bearing a
prescriber's DEA number that fails the checksum validation. Which action is legally
required in Virginia?
A. Dispense the prescription and notify the prescriber later
B. Contact the prescriber to verify the DEA number and correct it before dispensing
C. Refuse to fill and report to the DEA
D. Use the NPI number instead to validate the prescription
Correct Answer: B. Contact the prescriber to verify the DEA number and correct it
before dispensing
Rationale: Virginia regulations require the pharmacist to verify the DEA number and
ensure it is valid. If it fails validation, the pharmacist must not dispense until the
prescriber confirms and corrects the number. Reporting to the DEA is only for suspected
diversion or forgery, not for an administrative error.
Why Wrong:
A - Dispensing without correcting an invalid DEA number violates federal and state
law and could result in penalties.
C - Reporting to the DEA is excessive unless there is evidence of fraud or diversion,
not a simple typographical error.
D - The NPI is not a substitute for a DEA number on controlled substance
prescriptions.
Reference: Virginia Board of Pharmacy Regulations, 18 VAC 110-20-50; DEA
Practitioner's Manual
Q2. A patient on chronic warfarin therapy is prescribed metronidazole for a dental
infection. The pharmacist notes the interaction. What is the most appropriate action
regarding warfarin management?
A. Discontinue warfarin for the duration of metronidazole therapy
B. Reduce the warfarin dose by 50% and monitor INR closely
C. Continue warfarin unchanged and recheck INR in 1 week
D. Hold warfarin and start bridging with enoxaparin
Correct Answer: B. Reduce the warfarin dose by 50% and monitor INR closely
Rationale: Metronidazole inhibits CYP2C9, decreasing warfarin metabolism and
increasing INR. Proactive dose reduction (often 50%) with close INR monitoring is
recommended to prevent bleeding. Discontinuation or bridging is not standard for a short
course.
Why Wrong:
A - Discontinuing warfarin increases thromboembolic risk without a clear indication
for bridging.
C - Continuing unchanged risks supratherapeutic INR and bleeding.
Page 3
, D - Bridging is only for perioperative or high-thrombotic-risk situations, not for
antibiotic interaction.
Reference: Hansten & Horn, Drug Interactions Analysis and Management; Ansell et al.,
CHEST Guidelines
Q3. According to Virginia law, which of the following must be included on the label of
a dispensed prescription medication?
A. The drug's brand name and manufacturer
B. The prescriber's DEA number
C. The date of dispensing and the pharmacy's telephone number
D. The patient's diagnosis and the drug's expiration date
Correct Answer: C. The date of dispensing and the pharmacy's telephone number
Rationale: Virginia law requires the date of dispensing and the pharmacy's name, address,
and telephone number on the label. Brand name, DEA number, diagnosis, and expiration
date are not required on patient labels.
Why Wrong:
A - Brand name and manufacturer are not required by state law; generic name is
sufficient.
B - DEA number is for the prescription record, not the patient label.
D - Diagnosis is never required on a label; expiration date may be on the container but
not mandated on the label.
Reference: 18 VAC 110-20-160; Virginia Drug Control Act
Q4. A patient has a serum creatinine of 1.4 mg/dL, weighs 72 kg, and is 65 years old.
Calculate the estimated creatinine clearance using the Cockcroft-Gault equation.
Which value is closest?
A. 48 mL/min
B. 60 mL/min
C. 72 mL/min
D. 84 mL/min
Correct Answer: A. 48 mL/min
Rationale: Using Cockcroft-Gault: CrCl = [(140 - age) × weight] / (72 × SCr). For male:
(140-65=75) × 72 = 5400; 72 × 1.4 = 100.8; 5400/100.8 53.6 mL/min. For female,
multiply by 0.85. The closest option is 48 mL/min (likely assuming female).
Why Wrong:
B - 60 mL/min is too high and likely reflects an error in arithmetic or not adjusting for
age.
C - 72 mL/min would be if the serum creatinine were 1.0 mg/dL, not 1.4.
D - 84 mL/min is too high and suggests a miscalculation of the denominator.
Page 4
